We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Paladin Labs Announces the Canadian Launch of DigiFab™ Digoxin Immune Fab (Ovine)

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Paladin Labs Announces the Canadian Launch of DigiFab™ Digoxin Immune Fab (Ovine)"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Paladin Labs Inc. has announced the Canadian launch of DigiFab™ Digoxin Immune Fab (Ovine).

DigiFab™ is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose.

There are approximately 1.6 million digoxin prescriptions written annually in Canada.

Digoxin is known to have a narrow therapeutic window and patients can easily move from a therapeutic to toxic dose through excessive dosing, slow elimination and metabolism or through interactions with other drugs.

Digoxin toxicity can cause potentially life-threatening heart rhythm disturbances.

Paladin acquired the exclusive Canadian rights to market and sell DigiFab™ from BTG International Inc., in February 2010.